Efficacy and Feasibility of Time-restricted Eating on Cardiometabolic Health in Adults With Overweight/Obesity
EXTREME
1 other identifier
interventional
197
1 country
2
Brief Summary
In Spain, obesity epidemic is one of the leading contributors of chronic disease and disability. Obesity is associated with higher morbidity and all-cause mortality risk especially when fat is stored in the abdominal area (i.e., increased visceral adipose tissue, VAT). Although current approaches such as energy restriction may be effective at reducing body fat and improving cardiometabolic health, their long-term adherences are limited. Time-restricted eating (TRE; e.g., 8 hours eating: 16 hours fasting on a daily basis) is a recently emerged intermittent fasting approach with promising cardiovascular benefits. Results from pioneering pilot studies in humans are promising and suggest that simply reducing the eating time window from ≥12 to ≤8-10 hours/day improves cardiometabolic health. However, currently, there is no consensus regarding whether the TRE eating window should be aligned to the early or middle to late part of the day. The EXTREME study will investigate the efficacy and feasibility of three different 8 hours TRE schedules (i.e., early, late and self-selected) over 12 weeks on VAT (main outcome) and cardiometabolic risk factors (secondary outcomes) in adults with overweight/obesity and abdominal obesity. The final goal of the EXTREME study is to demonstrate the health benefits of a novel and pragmatic intervention for the treatment of obesity and related cardiometabolic risk factors; an approach readily adaptable to real-world practice settings, easy for clinicians to deliver, and intuitive for patients to implement and maintain in their lives.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2022
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 17, 2022
CompletedFirst Posted
Study publicly available on registry
April 5, 2022
CompletedStudy Start
First participant enrolled
April 11, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 6, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 6, 2023
CompletedNovember 29, 2023
November 1, 2023
11 months
January 17, 2022
November 28, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Change in visceral adipose tissue
Visceral adipose tissue will be assessed by Magnetic Resonance Imaging (MRI)
Change from baseline to 12 weeks
Secondary Outcomes (37)
Change in Hepatic fat content
Change from baseline to 12 weeks
Change in Pancreatic fat content
Change from baseline to 12 weeks
Change in Intramuscular fat content
Change from baseline to 12 weeks
Change in Hepatic elasticity
Change from baseline to 12 weeks
Change in Pancreatic elasticity
Change from baseline to 12 weeks
- +32 more secondary outcomes
Other Outcomes (1)
Epigenetic changes in clock genes
Change from baseline to 12 weeks
Study Arms (4)
Early time-restricted eating
EXPERIMENTALParticipants will eat ad libitum within an 8-hour early eating window. The first meal will be before 10 am (last meal before 18h). No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Late time-restricted eating
EXPERIMENTALParticipants will eat ad libitum within an 8-hour late eating window. The first meal will be at 13h or later (last meal not before 21h). No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Self-selected time-restricted eating
EXPERIMENTALParticipants will self-selecte an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Usual-care group
NO INTERVENTIONParticipants will receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Interventions
Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Participants will self-selected an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Eligibility Criteria
You may qualify if:
- Aged 30-60 years.
- Body mass index ≥25.0 and \<40 kg/m2
- Weight stability (within 3% of screening weight) for \>3 months prior to study entry.
- Sedentary lifestyle (\<150 min/week of moderate-vigorous intensity exercise) for \>3 months prior to study entry.
- Habitual eating window ≥12 hours.
- At least one of the following metabolic impairments:
- High-density lipoprotein (HDL) cholesterol concentration \<50 mg/dL for females and \<40 mg/dL for males.
- Low-density lipoprotein (LDL) cholesterol levels \>100 mg/dL (or on medication to treat elevated LDL cholesterol levels).
- Serum triglycerides concentration ≥150 mg/dL or on medication to treat elevated triglycerides.
- Systolic blood pressure \>130 mm Hg and/or diastolic blood pressure \>85 mm Hg or already being treated with anti-hypertension medications.
- Impaired glucose tolerance is defined as at least one of the following:
- Fasting plasma glucose (PG) \>100 mg/dL and \<125 mg/dL.
- Hemoglobin A1c between ≥5.7% and \<6.5%.
- Insulin resistance as measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA2-IR) \>1.8.
You may not qualify if:
- History of a major adverse cardiovascular event, clinically significant kidney, endocrine, or neurological disease, bariatric surgery, HIV/AIDS, known inflammatory and/or rheumatologic disease, cancer, or other medical condition in which fasting or exercise is contraindicated.
- Type 1 or Type 2 diabetes.
- Major psychiatric disorders, eating disorders, sleep disorders, or alcohol abuse.
- Regular use of medication or compounds that may affect study outcomes (e.g., antidiabetic, steroids, beta-blockers, antibiotics, prebiotics, probiotics and symbiotics).
- Participating in a weight loss or a weight-management program.
- Pregnancy and lactation or planned pregnancy (within the study period).
- Caregiver for a dependent requiring frequent nocturnal care/sleep interruptions. Shift workers with variable hours (e.g., nocturnal). Frequent travel over time zones during the study period.
- Fear of needles and claustrophobia to magnetic resonance imaging (MRI).
- Being unable to understand and to accept the instructions or the study objectives and protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Universidad de Granadalead
- Universidad Pública de Navarracollaborator
Study Sites (2)
Universidad Pública de Navarra
Pamplona, Navarre, 31006, Spain
University of Granada
Granada, 18011, Spain
Related Publications (2)
Clavero-Jimeno A, Dote-Montero M, Migueles JH, Camacho-Cardenosa A, Medrano M, Alfaro-Magallanes VM, Oses M, Carneiro-Barrera A, de Cabo R, Munoz-Torres M, Labayen I, Ruiz JR. Time-Restricted Eating and Sleep, Mood, and Quality of Life in Adults With Overweight or Obesity: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2025 Jun 2;8(6):e2517268. doi: 10.1001/jamanetworkopen.2025.17268.
PMID: 40560588DERIVEDDote-Montero M, Clavero-Jimeno A, Merchan-Ramirez E, Oses M, Echarte J, Camacho-Cardenosa A, Concepcion M, Amaro-Gahete FJ, Alcantara JMA, Lopez-Vazquez A, Cupeiro R, Migueles JH, De-la-O A, Garcia Perez PV, Contreras-Bolivar V, Munoz-Garach A, Zugasti A, Petrina E, Alvarez de Eulate N, Goni E, Armendariz-Brugos C, Gonzalez Cejudo MT, Martin-Rodriguez JL, Idoate F, Cabeza R, Carneiro-Barrera A, de Cabo R, Munoz-Torres M, Labayen I, Ruiz JR. Effects of early, late and self-selected time-restricted eating on visceral adipose tissue and cardiometabolic health in participants with overweight or obesity: a randomized controlled trial. Nat Med. 2025 Feb;31(2):524-533. doi: 10.1038/s41591-024-03375-y. Epub 2025 Jan 7.
PMID: 39775037DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jonatan R. Ruiz, PhD
Universidad de Granada
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 17, 2022
First Posted
April 5, 2022
Study Start
April 11, 2022
Primary Completion
March 6, 2023
Study Completion
March 6, 2023
Last Updated
November 29, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share